SCHEMBL1727787

SCHEMBL1727787

CCC1=CC(=O)NC1=O.O=C1C=CC(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
CCR6 P51684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38085 0.91
Water SCHEMBL28091835 0.89
Ammonia Solution, Strong SCHEMBL2328420 0.89
Hydrochloric Acid SCHEMBL28905030 0.89
Benzene SCHEMBL27704544 0.87
SCHEMBL28549319 0.84 GSK3A (0.42) GSK3AGSK3BCCR6
Pyrrole SCHEMBL2280196 0.82
SCHEMBL28201436 0.82
SCHEMBL3695978 0.80
Carbamic Acid SCHEMBL28123766 0.80 FGFR1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC (US) 2018-09-20 US claimed
US-9980926-B1 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2018-05-29 US claimed
US-10806708-B2 Affinity medicant conjugate AF CHEMICALS LLC (US) 2020-10-20 US disclosed
US-10285955-B2 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2019-05-14 US disclosed
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC (US) 2018-09-20 US disclosed
US-9980926-B1 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2018-05-29 US disclosed
US-9381178-B2 Affinity medicant conjugate AF CHEMICALS LLC (US) 2016-07-05 US disclosed
US-20160015658-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC 2016-01-21 US disclosed
US-20150290152-A1 AFFINITY MEDICANT CONJUGATE AF CHEMICALS, LLC 2015-10-15 US disclosed
US-8921124-B2 Pyrazole-based cyanine dye WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-12-30 US disclosed
WO-2012033298-A3 METHOD FOR MANUFACTURING A NOX GAS SENSOR, AND NOX GAS SENSOR MANUFACTURED USING SAME 일진머티리얼즈 주식회사 (KR) 2012-05-10 WO disclosed
CN-1733721-A Maleimide derivative and its preparation method and uses DONG SHUYOU (CN) 2006-02-15 CN disclosed
US-20050113304-A1 Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins ARMY, GOVERNMENT OF THE UNITED STATES DEPARTMENT OF THE ARMY (US) 2005-05-26 US disclosed
US-20050008602-A1 Oligopeptides for promoting hair growth SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) 2005-01-13 US disclosed
US-6573244-B1 Compound in purified and isolated form or salts, esters, amides, and acyl forms thereof, selected from peptides having specified amino acid sequences THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2003-06-03 US disclosed
EP-1310511-A2 Oligopeptides for promoting hair growth Sumitomo Electric Industries, Ltd. (JP) 2003-05-14 EP disclosed
US-20030086893-A1 Oligopeptides for promoting hair growth SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) 2003-05-08 US disclosed
WO-2000069891-A9 PREVINS AS SPECIFIC INHIBITORS AND THERAPEUTIC AGENTS FOR BOTULINUM TOXIN B AND TETANUS NEUROTOXINS DEPT OF THE ARMY (US) 2002-07-04 WO disclosed
EP-1179010-A2 PREVINS AS SPECIFIC INHIBITORS AND THERAPEUTIC AGENTS FOR BOTULINUM TOXIN B AND TETANUS NEUROTOXINS U.S. Army Medical Research and Materiel Command (US) 2002-02-13 EP disclosed
WO-2000069891-A2 PREVINS AS SPECIFIC INHIBITORS AND THERAPEUTIC AGENTS FOR BOTULINUM TOXIN B AND TETANUS NEUROTOXINS DEPARTMENT OF THE ARMY (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015658-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A GSK3A 2180/4885GSK3B 2603/4885CCR6 291/4885
US-20150290152-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A GSK3A 2180/4885GSK3B 2603/4885CCR6 291/4885
US-10285955-B2 Affinity medicant conjugate FCER2, HDGF, FCGR2A GSK3A 2180/4885GSK3B 2603/4885CCR6 291/4885
US-20050008602-A1 Oligopeptides for promoting hair growth HDGF, HGF, AREG GSK3A 2039/4885GSK3B 2043/4885CCR6 1140/4885
US-10806708-B2 Affinity medicant conjugate FCER2, HDGF, FCGR2A GSK3A 2180/4885GSK3B 2603/4885CCR6 291/4885
US-20180263927-A1 AFFINITY MEDICANT CONJUGATE FCER2, HDGF, FCGR2A GSK3A 2180/4885GSK3B 2603/4885CCR6 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.